Literature DB >> 15718260

Effects of atrial natriuretic peptide on the extrasplenic microvasculature and lymphatics in the rat in vivo.

Zoë L S Brookes1, Susan Kaufman.   

Abstract

We developed a novel model using fluorescent intravital microscopy to study the effect of atrial natriuretic peptide (ANP) on the extrasplenic microcirculation. Continuous infusion of ANP into the splenic artery (10 ng min(-1) for 60 min) of male Long-Evans rats (220-250 g, n = 24) induced constriction of the splenic arterioles after 15 min (-7.2 +/- 6.6% from baseline diameter of 96 +/- 18.3 microm, mean +/- S.E.M.) and venules (-14.4 +/- 4.0% from 249 +/- 25.8 microm; P < 0.05). At the same time flow did not change in the arterioles (from 1.58 +/- 0.34 to 1.27 +/- 0.27 ml min(-1)), although it decreased in venules (from 1.67 +/- 0.23 to 1.15 +/- 0.20 ml min(-1)) and increased in the lymphatics (from 0.007 +/- 0.001 to 0.034 +/- 0.008 ml min(-1); P < 0.05). There was no significant change in mean arterial pressure (from 118 +/- 5 to 112 +/- 5 mmHg). After continuous ANP infusion for 60 min, the arterioles were dilated (108 +/- 16 microm, P < 0.05) but the venules remained constricted (223 +/- 24 microm). Blood flow decreased in both arterioles (0.76 +/- 0.12 ml min(-1)) and venules (1.03 +/- 0.18 ml min(-1); P < 0.05), but was now unchanged from baseline in the lymphatics (0.01 +/- 0.001 ml min(-1)). This was accompanied by a significant decrease in MAP (104 +/- 5 mmHg; P < 0.05). At 60 min, there was macromolecular leak from the lymphatics, as indicated by increased interstitial fluorescein isothiocyanate-bovine serum albumin fluorescence (grey level: 0 = black; 255 = white; from 55.8 +/- 7.6 to 71.8 +/- 5.9, P < 0.05). This study confirms our previous proposition that, in the extrasplenic microcirculation, ANP causes greater increases in post- than precapillary resistance, thus increasing intrasplenic capillary hydrostatic pressure (P(c)) and fluid efflux into the lymphatic system. Longer-term infusion of ANP also increases Pc, but this is accompanied by increased 'permeability' of the extrasplenic lymphatics, such that fluid is lost to perivascular third spaces.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718260      PMCID: PMC1464482          DOI: 10.1113/jphysiol.2005.083147

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  40 in total

Review 1.  Extracellular fluid and its proteins: dehydration, shock, and recovery.

Authors:  M A Holliday
Journal:  Pediatr Nephrol       Date:  1999-11       Impact factor: 3.714

2.  Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs.

Authors:  R L Woods; M J Jones
Journal:  Am J Physiol       Date:  1999-05

3.  An effective and economical solution for digitizing and analyzing video recordings of the microcirculation.

Authors:  K E Norman
Journal:  Microcirculation       Date:  2001-08       Impact factor: 2.628

4.  Evidence for a second valve system in lymphatics: endothelial microvalves.

Authors:  J Trzewik; S K Mallipattu; G M Artmann; F A Delano; G W Schmid-Schönbein
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

5.  Atrial natriuretic factor increases splenic microvascular pressure and fluid extravasation in the rat.

Authors:  R Sultanian; Y Deng; S Kaufman
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

6.  Focal adhesion molecules expression and fibrillin deposition by lymphatic and blood vessel endothelial cells in culture.

Authors:  Elisabetta Weber; Antonella Rossi; Raffaella Solito; Giovanni Sacchi; Margherita Agliano'; Renato Gerli
Journal:  Microvasc Res       Date:  2002-07       Impact factor: 3.514

7.  Differential effects of intravenous anaesthetic agents on the response of rat mesenteric microcirculation in vivo after haemorrhage.

Authors:  Z L S Brookes; N J Brown; C S Reilly
Journal:  Br J Anaesth       Date:  2002-02       Impact factor: 9.166

8.  Microvascular effects of atrial natriuretic peptide (ANP) in man: studies during high and low salt diet.

Authors:  A J Houben; M M Krekels; N C Schaper; M J Fuss-Lejeune; S A Rodriguez; P W de Leeuw
Journal:  Cardiovasc Res       Date:  1998-08       Impact factor: 10.787

9.  Deciphering vascular endothelial cell growth factor/vascular permeability factor signaling to vascular permeability. Inhibition by atrial natriuretic peptide.

Authors:  Ali Pedram; Mahnaz Razandi; Ellis R Levin
Journal:  J Biol Chem       Date:  2002-09-03       Impact factor: 5.157

Review 10.  The atrial natriuretic peptide: a changing view.

Authors:  S Rubattu; M Volpe
Journal:  J Hypertens       Date:  2001-11       Impact factor: 4.844

View more
  5 in total

1.  Permeability and contractile responses of collecting lymphatic vessels elicited by atrial and brain natriuretic peptides.

Authors:  Joshua P Scallan; Michael J Davis; Virginia H Huxley
Journal:  J Physiol       Date:  2013-07-29       Impact factor: 5.182

2.  Constriction of rat extra-splenic veins to lipopolysaccharide involves endothelin-1.

Authors:  Arnaud Mansart; Lewis J Ruff; Mark P Ariaans; Jonathan J Ross; Charles S Reilly; Nicola J Brown; Susan Kaufman; Zoë L S Brookes
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-16       Impact factor: 3.000

3.  Atorvastatin reduces endotoxin-induced microvascular inflammation via NOSII.

Authors:  Caroline C McGown; Zoë L S Brookes; Paul G Hellewell; Jonathan J Ross; Nicola J Brown
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-14       Impact factor: 3.000

4.  Atrial natriuretic peptide modulation of albumin clearance and contrast agent permeability in mouse skeletal muscle and skin: role in regulation of plasma volume.

Authors:  Fitz-Roy E Curry; Cecilie Brekke Rygh; Tine Karlsen; Helge Wiig; Roger H Adamson; Joyce F Clark; Yueh-Chen Lin; Birgit Gassner; Frits Thorsen; Ingrid Moen; Olav Tenstad; Michaela Kuhn; Rolf K Reed
Journal:  J Physiol       Date:  2009-11-30       Impact factor: 5.182

5.  The nociceptin/orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo.

Authors:  Zoë L S Brookes; Emily N Stedman; Nicola J Brown; Christopher P Hebbes; Remo Guerrini; Girolamo Calo; Charles S Reilly; David G Lambert
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.